BioCryst Pharmaceuticals, Inc.
NASDAQ:BCRXBiotechnology
+$0.09 today
- Market cap
- $1.88B
- Beta
- 0.56
- P/E (TTM)
- -4.8
- EPS (TTM)
- -$1.89
Volume 3.78M
Average 4.85M
Returns on capital
BioCryst Pharmaceuticals, Inc. management
Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.
Return Metrics
ROE, ROIC & ROA over time
ROE
-221.4%
avg 73.6%
ROIC
105.2%
avg -35.3%
ROA
51.3%
avg -36.9%
Analysis
ROIC is currently the strongest return metric at 105.2% versus its period average of -35.3%. 2 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Leadership
Who runs the company?
Review the executive team, tenure, compensation, and ownership.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|
Charles K. Gayer | CEO, President & Director | USD 1.38M | 55 | 0 | <0.01% |
Alane Barnes | Senior Vice President, Chief Legal Officer & Corporate Secretary | USD 1.11M | 60 | — | — |
Babar Ghias | Chief Financial Officer & Head of Corporate Development | USD 948.42K | 47 | 268.70K | 0.13% |
William Sheridan MBBS | Chief Development Officer | USD 784.09K | 71 | — | — |
Yarlagadda S. Babu | Chief Discovery Officer | USD 691.45K | 73 | 0 | <0.01% |
John Ruesch | Chief Technical Operations Officer | — | — | — | — |
Jinky Ang Rosselli | Chief Data Innovation Officer | — | — | — | — |
Stephanie Angelini | Chief People Officer & Communications Officer | — | — | — | — |
Nick Wilder | Manager of Investor Relations | — | — | — | — |
David W. Jenkins | Chief Scientific Officer | — | — | — | — |
Compensation is shown in the reported currency; data updated Nov 7, 2026.
Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Dec 22, 2025.
Insider trading
Are insiders buying or selling?
Follow recent insider purchases and sales reported on Form 4.
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
0
$0.00
Sells
9
$4.07M
Net Transaction Value
−$4.07M
Net selling
Most Active
Barnes Alane P
7 transactions
Transactions sorted by date, descending.
| Type | |||
|---|---|---|---|
| May 18, 26May 18, 2026 | McKee Amy E Direct | Sell | $100.3K$100,284.60 |
| May 13, 26May 13, 2026 | Barnes Alane P Direct | Sell | $596.3K$596,250.00 |
| Mar 20, 26Mar 20, 2026 | HEGGIE THERESA Direct | Sell | $504.8K$504,822.63 |
| Mar 16, 26Mar 16, 2026 | Barnes Alane P Direct | Sell | $1.4M$1,372,500.00 |
| Dec 22, 25Dec 22, 2025 | Barnes Alane P Direct | Sell | $166.6K$166,563.45 |
| Dec 15, 25Dec 15, 2025 | Barnes Alane P Direct | Sell | $162.3K$162,256.50 |
| Dec 3, 25Dec 3, 2025 | Barnes Alane P Direct | Sell | $151.2K$151,240.50 |
| Dec 2, 25Dec 2, 2025 | Barnes Alane P Direct | Sell | $367.2K$367,215.52 |
| Dec 1, 25Dec 1, 2025 | Barnes Alane P Direct | Sell | $646.5K$646,510.62 |
Summary
Insiders reported 0 buys worth $0.00 and 9 sells worth $4.07M over the last 12 months. That adds up to net selling of $4.07M. Barnes Alane P was the most active insider with 7 transactions.
Growth analysis
Is management growing the business?
Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | -1.7% (5yr)4 analysts |
| Revenue | N/A | N/A | +47.8% | +4.7% (5yr)6 analysts |
| Net Income | N/A | N/A | N/A | -1.6% (5yr)6 analysts |
| EBIT | N/A | N/A | N/A | +3.4% (5yr)6 analysts |
Analysis
Recent growth has been strongest in Revenue at +47.8% over three years. Forward estimates point to Revenue at +4.7% (5yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Who does BioCryst Pharmaceuticals, Inc. compete with?
Open similar companies to compare how their management teams allocate capital.
Competitors
Peer companies in the same sector
Questions
Management questions
Common questions about BCRX's management, answered from reported figures.
Who manages BCRX?
BioCryst Pharmaceuticals, Inc. (BCRX) lists 10 active executives. The top listed executive is Yarlagadda S. Babu, Chief Discovery Officer.
Are BCRX insiders buying or selling?
Recent insider activity shows net buying of $37.20M.
Continue the stock analysis
Jump to another research area for this company.